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StereotypyMyricitrin is a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity,
including anxiolytic-like action. Nitric oxide inhibitors blocked the behavioral effects of apomorphine,
suggesting an antipsychotic-like effect. Furthermore, PKC inhibition reduced psychotic symptoms in acute
mania patients and blocked amphetamine-induced hyperlocomotion, suggesting a potential antipsychotic-
like effect. The present study evaluated the effects of myricitrin in animal models that assess antipsychotic-
like effects (apomorphine-induced stereotypy and climbing and the paw test) and extrapyramidal side effects
(catalepsy test and paw test). Olanzapine was used as a positive control. 7-Nitroindazole (7-NI), a NOS
inhibitor, and L-arginine, a NO precursor, were used to evaluate nitrergic modulation, and tamoxifen was used
to test the effect of PKC inhibition. In mice, myricitrin dose-dependently and olanzapine blocked the
stereotypy and climbing induced by apomorphine at doses that did not induce catalepsy. 7-Nitroindazole
also blocked apomorphine-induced stereotypy and climbing, whichwere reversed by L-arginine pretreatment.
L-arginine only attenuated the effects of myricitrin on apomorphine's effects. Tamoxifen also blocked
apomorphine-induced stereotypy and climbing. In the paw test in rats, myricitrin and olanzapine increased
hindlimb retraction time at doses that did not affect forelimb reaction time, whereas haloperidol affected
both parameters at the same dose. Myricitrin did not induce catalepsy in the bar test. Tamoxifen did not
affect hindlimb retraction time or forelimb retraction time, whereas 7-NI signiﬁcantly increased hindlimb
reaction time. Thus, myricitrin exhibited an antipsychotic-like proﬁle at doses that did not induce catalepsy,
and this effect may be related to nitrergic action.orter; FRT, forelimb retraction
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Antipsychotics are effective drugs for controlling psychotic
symptoms in somemental disorders, such as schizophrenia. However,
both typical (e.g., haloperidol) and atypical (e.g., clozapine andolanzapine) antipsychotics exert troublesome side effects that
decrease adherence to treatment and affect the quality of life of
patients (Novick et al., 2009; Serretti and Chiesa, 2011; Tandon et al.,
2008). Furthermore, schizophrenia patients refractory to current
antipsychotics are unlikely to respond to new antipsychotics that
target the dopamine D2 receptor (Stone et al., 2010). Thus, new
antipsychotics drugs are necessary.
Nitric oxide (NO) can positively modulate dopaminergic neuro-
transmission (Fig. 1), since it appears to block dopamine reuptake and
to facilitate postsynaptic activation (Bernstein et al., 2005; Del Bel and
Guimarães, 2000; Fujiyama and Masukos, 1996; Hong et al., 2005;
Pires et al., 2003; West et al., 2002), and drugs that inhibit NO may
have potential antipsychotic effects (Bernstein et al., 2005;West et al.,
2002; Wiley, 1998). 7-Nitroindazole (7-NI) and NG-nitro-L-arginine
(L-NOARG) are speciﬁc and nonspeciﬁc NO synthase inhibitors,
respectively, and attenuate the disruption of prepulse inhibition
induced by methylphenidate and phencyclidine, proposed models of
antipsychotic action (Geyer and Ellenbroek, 2003; Issy et al., 2009;
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Fig. 1. Effects of nitric oxide (NO) on dopamine (DA) transmission. (1) Glutamate (Glu)
activates N-methyl-D-aspartate receptors (NMDAr) in NO neurons, opening calcium
channels and leading to Ca2+ inﬂux. (2) Increased intracellular Ca2+ activates neuronal
nitric oxide synthase (nNOS), generating NO from L-arginine (L-arg). (3) Nitric
oxide diffuses to the extracellular space, inhibiting the dopamine transporter (DAT),
which reduces DA reuptake and increases extracellular DA. (4) Dopamine activates
postsynaptic D2 receptors. (5) Nitric oxide also directly facilitates D2 activation or
postsynaptic transduction mechanisms, increasing DA transmission. (6) Nitric oxide also
increases Glu release, which exacerbates its effect on NO production. Apomorphine acts at
postsynaptic D2 receptors, and amphetamine stimulates presynaptic DA release and
decreases DA reuptake. Myricitrin and 7-NI block NO synthesis, reducing the facilitatory
effect of NO on DA transmission. Solid line: activation; dashed line: inhibition.
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mice, L-NOARG and 7-NI attenuated the increase in locomotor activity
induced by D1 and D2 agonists (Starr and Starr, 1995). Locomotor
hyperactivity induced by dopamine agonists is another animal model
for the study of antipsychotic-like action (Geyer and Ellenbroek, 2003).
Clinical studies found changes in NO synthase (NOS)-containing
interneurons in frontal and limbic cortices in schizophrenia patients
(Akbarian et al., 1993a,b). Moreover, the addition of methylene
blue, which blocks NO activity on soluble guanylyl cyclase, to
neuroleptic treatment modestly improved psychotic symptoms
(Deutsch et al., 1997).
Nitric oxide inhibition has also been associated with catalepsy.
Nitric oxide synthase inhibitors induced catalepsy in mice (Del Bel et
al., 1998, 2002, 2005), an effect that was antagonized by pretreatment
with L-arginine, a NO precursor (Del Bel et al., 2005; Marras et al.,
1995; Narkevich et al., 2005). The effects of NO on prepulse inhibition
and catalepsy may involve dopaminergic mediation because the
cataleptic effect of a NOS inhibitor was reversed by apomorphine, a
dopamine agonist, and NO appeared to increase dopamine in the
striatum (Del Bel et al., 2005). Furthermore, haloperidol attenuated
the increase in NO levels induced by neonatal ventral hippocampus
lesion, an animal model of schizophrenia (Negrete-Diaz et al., 2010).
Based on the hypothesis that protein kinase C (PKC) inhibition is
an important target for mood stabilizers, tamoxifen, a PKC inhibitor,
was tested in clinical trials for the treatment of acute episodes of
mania (Bebchuk et al., 2000; DiazGranados and Zarate, 2008; Kulkarni
et al., 2006; Yildiz et al., 2008; Zarate et al., 2007). The controlled
studies with tamoxifen monotherapy showed a consistent antimanic
effect (Yildiz et al., 2008; Zarate et al., 2007), which corroborated the
initial hypothesis of PKC inhibition. Moreover, tamoxifen blocked
amphetamine-induced hyperlocomotion, an animal model of mania
(Einat et al., 2007; Sabioni et al., 2008). However, behavioral changes
(e.g., hyperlocomotion) induced by amphetamine administration arealso proposed as an animal model of antipsychotic-like effects (Bardin
et al., 2006;Depoortere et al., 2003; Leite et al., 2008; Porsolt et al., 1993,
2010), and mania patients can show psychotic symptoms (Goodwin
and Jamison, 2007). Kulkarni et al. (2006) and Yildiz et al. (2008)
observed a reduction in psychotic symptoms in mania patients treated
with tamoxifen. Moreover, chronic administration of clozapine and
haloperidol reduced PKC activity and levels in discrete brain areas (e.g.,
hippocampus and cortex), which could be relevant to the antipsychotic
and antimanic effects of these drugs (Dwivedi and Pandey, 1999).
Interestingly, chronic clozapine and haloperidol decreased mRNA and
protein levels of the PKC α and ε isozymes (Manji and Lenox, 1999).
Thus, PKC inhibitors may also have antipsychotic-like effects and may
be an interesting target for new antipsychotic drugs.
Myricitrin is a ﬂavonoid extracted from some plants (Pouteria
gender, Manilkara zapota, Eugenia uniﬂora, among others) and has
anxiolytic and antinociceptive effects. Myricitrin increases the
percentage of entries into and time spent on the open arms of the
elevated plus maze, although this effect presents a bell-shaped curve,
decreasing at high doses (Fernandez et al., 2009). Myricitrin also has
antinociceptive action in models of acute and chronic pain (Meotti
et al., 2006a, b, 2007a, b). For example, myricitrin decreases paw
edema and reduces allodynia caused by intraplantar administration
of complete Freund's adjuvant or induced by partial constriction of the
sciatic nerve (Meotti et al., 2006a). Myricitrin appears to inhibit NO
synthesis and reduce iNOS overexpression induced by lipopolysac-
charide (Chen et al., 2000). Pretreatment with L-arginine prevented
the antinociceptive effect of myricitrin in an abdominal writhing
model induced by acetic acid (Meotti et al., 2006b). Myricitrin also
blocked the effects of PMA, a PKC activator, administration on licking
behavior and activation of PKCα and PKCε (Meotti et al., 2006b).
Additionally, myricitrin may act on small-conductance calcium-gated
potassium channels and inhibit calcium inﬂux. Furthermore, it also
inhibits p38 MAPK phosphorylation induced by interleukin-1β and
tumor necrosis factor α (Meotti et al., 2007b).
Several animal behavioral models have been used to evaluate
antipsychotic-like drugs, and, among them, behavioral changes
induced by direct and indirect dopaminergic agonists are frequently
used (Geyer and Ellenbroek, 2003; Porsolt et al., 2010). The behaviors
observed include stereotypy (e.g., repetitive snifﬁng, rearing, gnawing,
licking, and head bobbing) and climbing (i.e., when a mouse climbs
the walls of cage and holds the wire mesh with two to four paws).
Apomorphine-induced climbing has been mainly related to mesolim-
bic dopaminergic activity, whereas stereotypy induced by apomor-
phine appears to involve striatal D2 receptors (Porsolt et al., 1993,
2010). In response to apomorphine, the preferential blockade of
climbing over stereotypy is hypothesized to indicate an atypical
antipsychotic proﬁle (Geyer and Ellenbroek, 2003). In the paw test,
which was developed to differentiate typical and atypical antipsy-
chotic drugs, rats treated with test drugs are placed on a platform
with four holes (one for each paw), and the time to withdraw the
forelimbs and hindlimbs from the holes is the independent variable
(Cools et al., 1995; Ellenbroek et al., 1987; Ellenbroek and Cools, 1988).
The paw test was validated with several antipsychotic and non-
antipsychotic drugs, showing good predictive validity (Cools et al.,
1995; Ellenbroek et al., 1987; Ellenbroek and Cools, 1988). Catalepsy is
considered the relative incapacity of an animal to change an unusual
posture imposed by the experimenter (Porsolt et al., 1993). This test is a
useful procedure for assessing potential extrapyramidal motor side
effects (Bardin et al., 2006; Porsolt et al., 1993, 2010). In the present
study, apomorphine-induced climbing and stereotypy and the paw test
were used to predict potential antipsychotic effects, and catalepsy was
used to predict extrapyramidal side effects. In these models, typical and
atypical antipsychotics were hypothesized to exert differential behav-
ioral proﬁles. Typical antipsychotics block stereotypy and climbing
induced by apomorphine, induce catalepsy, and impair forelimb and
hindlimb retraction time in the paw test at the same dose. Atypical
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climbing, do not induce catalepsy (or induce it at only high doses), and
impair hindlimb retraction time at a lower dose than is necessary to
impair forelimb retraction time (Cools et al., 1995; Ellenbroek et al.,
1987; Ellenbroek and Cools, 1988; Geyer and Ellenbroek, 2003; Porsolt
et al., 1993, 2010).
Based on the aforementioned considerations, myricitrin, similar to
other NOS inhibitors, was hypothesized to exert antipsychotic-like
effects. Therefore, the objective of the present study was to evaluate
the effects of myricitrin in animal models of antipsychotic action (i.e.,
apomorphine-induced stereotypy and climbing in mice and the paw
test with rats) and extrapyramidal side effects (i.e., catalepsy test and
paw test) at doses that do not alter locomotor activity (Bardin et al.,
2006; Costall et al., 1978; Depoortere et al., 2003; Echeverry et al.,
2007; Geyer and Ellenbroek, 2003; Leite et al., 2008; Porsolt et al.,
1993; Protais et al., 1976). Furthermore, although monotherapy is the
ﬁrst treatment option for schizophrenia, several patients do not
respond satisfactorily to this approach, so a second drug is often added
to the pharmacotherapy. Thus, the present study also evaluated the
effects of a myricitrin and olanzapine combination on stereotypy and
climbing induced by apomorphine.
2. Methods
2.1. Animals
Animals were male adult Swiss albino mice (30–40 g, n=511) and
maleWistar rats (250–350 g, totaln=93) fromourownbreeding stock.
They were kept in groups in polypropylene cages (41×34×16 cm;
4–5 rats per cage and 20 mice per cage) with wood shavings as
bedding, under controlled conditions of light (12 h/12 h light/dark
cycle, lights on at 7:00 a.m.) and temperature (22±2 °C). The animals
had free access to water and food throughout the experiment. All
experimentswere performed in accordancewith theNational Institutes
of Health Guide for the Care and Use of Laboratory Animals and were
approved by the Ethics Committee for Animal Experiments, Biological
Sciences Sector, Federal University of Parana (protocol number 385).
2.2. Drugs and drug administration
Myricitrin was obtained from leaves of Eugenia uniﬂora (known as
Brazilian cherry tree) collected at Daniela Beach, Florianópolis. It was
isolated by the Department of Chemistry, Federal University of Santa
Catarina, and identiﬁed by spectral analysis (i.e.,
1
H nuclear magnetic
resonance,
13
C nuclear magnetic resonance) and compared with the
published spectra (Agrawal, 1989). The chemical purity was N98%,
determined by high-performance liquid chromatography. Myricitrin
was dissolved in Tween 80 followed by saline and administered
intraperitoneally (i.p.) at doses of 5, 10, and 30 mg/kg.
Olanzapine (1, 5, and 10mg/kg; Zyprexa, Eli Lilly, São Paulo, Brazil),
haloperidol (0.25, 0.5, and 1.0 mg/kg; Haldol, Jansen-Cilag, São Paulo,
Brazil), L-arginine (200, 400, and 600 mg/kg; Sigma, USA), and
tamoxifen (1.0 mg/kg; Sigma) were dissolved in saline and adminis-
tered i.p. Apomorphine (1.0 mg/kg; Sigma) was dissolved in distilled
water and administered subcutaneously (s.c.). 7-Nitroindazole (3 and
6 mg/kg; Sigma) was dissolved in corn oil and maintained in ice until
administration. For the test of apomorphine-induced stereotypy, 7-NI
was administered intracerebroventricularly (i.c.v.) in a constant volume
of 2 μl per site using the free-handmethod (Laursen and Belknap, 1986;
Sabioni et al., 2008). In the paw test, 7-NI was administered i.p.
All drugs were prepared freshly just before the experiments.
Drugs were administered in a constant volume of 1 ml/kg for rats
and 10 ml/kg for mice (unless otherwise speciﬁed). The doses were
based on previous studies (Bardin et al., 2006; Del Bel et al., 1998; Issy
et al., 2009; Meotti et al., 2006a, 2006b; Protais et al., 1976; Sabioni et
al., 2008). Olanzapine and haloperidol were chosen because they aretypical and atypical, respectively, antipsychotic drugs commonly
used clinically and frequently used as a positive control in preclinical
studies (e.g., Bardin et al., 2006; Cools et al., 1995). Tamoxifen is the
only PKC inhibitor used clinically that has good penetration in the
central nervous system (Bebchuk et al., 2000; Yildiz et al., 2008;
Zarate et al., 2007).
2.2.1. Free-hand method for i.c.v. administration
The free-hand method for i.c.v. administration was based on
previous studies (Baretta et al., 2001; Laursen and Belknap, 1986;
Sabioni et al., 2008). Brieﬂy, 15 min before apomorphine administra-
tion, the mice received light anesthesia with enﬂurane. A hypodermic
needle (0.4 mmouter diameter) attached to a cannula linked to a 10 μl
Hamilton syringe was inserted through the skull (1 mm to the right or
left of amidpoint in a line drawn through the anterior base of the ears).
This needlewas lowered 2 mm into themouse's brain. 7-Nitroindazole
or its vehicle was administered in a constant volume (0.2 μl) over a
period of 25 s, and the needle was left in place for an additional 25 s to
allow for diffusion. After the experiments, the mice were sacriﬁced by
deep anesthesia, and their brains were dissected and macroscopically
examined. Mice that exhibited substantial bleeding or misplaced
injection sites were discarded from the analysis. This occurred with 6
mice in the experiment with 7-NI and with 10 mice in the experiment
with 7-NI plus L-arginine (equally distributed across groups).
2.3. Behavioral tests
2.3.1. Apomorphine-induced stereotypy and climbing
Mice were isolated in wire-mesh cages (30×15×19 cm; vertical
bars 1 cm apart, 2 mm diameter) for 30 min and then treated with
myricitrin (5 or 10 mg/kg, i.p.), olanzapine (10 mg/kg, i.p.), or saline.
After 30 min, theywere injectedwith apomorphine (1 mg/kg, s.c.) and
observed for 90 min at 10 min intervals for signs of stereotypy based
on the following scale: 0 (asleep or stationary), 1 (active), 2 (active
with predominantly stereotyped snifﬁng and rearing), 3 (stereotyped
snifﬁngwith bursts of licking and/or gnawing and biting), 4 (continual
licking and/or gnawing of cage grids; Chinen et al., 2006).
In the same mice, climbing behavior was also assessed for 90 min
at 10 min intervals according to the following scale: 0 (no climbing),
1 (climbing with two forepaws only), 2 (climbing with four paws;
Marcais et al., 1978; Protais et al., 1976). Total scores were calculated
by summing the scores recorded for each 10 min interval.
To determine the participation of NO and PKC, we evaluated the
effects of tamoxifen (1 mg/kg, i.p.) and 7-NI (3 and 6 mg/kg, i.c.v.) on
apomorphine-induced climbing and stereotypy. The protocol was the
same as previously described for the experiments with olanzapine
and myricitrin, but 7-NI was administered i.c.v.
L-arginine pretreatment was used to evaluate the role of NO in
the effects of myricitrin in the apomorphine tests. First, we evaluated
the ability of 200, 400, and 600 mg/kg L-arginine (i.p.) to reverse
the effects of 7-NI in the apomorphine tests to establish the minimum
effective dose, which was found to be 200 mg/kg. Mice were then
pretreated with 200 mg/kg L-arginine (i.p.). Ten minutes later, they
received myricitrin (10 mg/kg, i.p.) or saline, followed 30 min later
by apomorphine treatment (1 mg/kg, s.c.). The animals were then
observed for stereotypy and climbing as described earlier.
2.3.2. Catalepsy test
Catalepsy was measured using the bar test (Bardin et al., 2006;
Pires et al., 1996) in two situations: (1) saline pretreatment before
administration of the test drug (myricitrin or olanzapine) or saline
and (2) haloperidol (0.25 or 1.0 mg/kg) pretreatment before
administration of the test drug or saline. Mice were habituated to
the test room for 30 min and then treated with haloperidol (0.25 or
1.0 mg/kg, i.p.) or saline. After 30 min, the mice received myricitrin
(10 or 30 mg/kg, i.p.), olanzapine (10 mg/kg, i.p.), or saline. Thirty
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Fig. 2.Effects ofmyricitrin (5–10 mg/kg) andolanzapine (10 mg/kg) on(A) apomorphine-
induced stereotypy scores and (B) apomorphine-induced climbing scores. Data are
expressed as mean+SEM (n=7–10 per group). ***pb0.001, compared with control
(saline+saline); ###pb0.001, compared with apomorphine+saline. Myr5, 5 mg/kg
myricitrin; Myr10, 10 mg/kg myricitrin; Olanz, 10 mg/kg olanzapine.
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test. Each mouse was individually placed on a table with its forepaw
positioned on a cylindrical glass bar (diameter, 0.4 cm; width, 5 cm)
at a height of 4 cm. The time that the mouse maintained both
forepaws on the bar was recorded three times, with a 1 min intertrial
interval. Themaximum time of each trial was 30 s, and the summation
of the three trials was calculated.
2.3.3. Paw test
The paw test was performed according to Ellenbroek and
colleagues (Cools et al., 1995; Ellenbroek et al., 1987, 1996, 2001;
Ellenbroek and Cools, 1988). Brieﬂy, the apparatus was a wooden
platform (30×30 cm, elevated 20 cm above the ﬂoor) that contained
four holes, two with a 4 cm diameter for the forelimbs and two with a
5 cm diameter for the hindlimbs (Ellenbroek and Cools, 1988). The
rats were individually housed 24 h before the test. For habituation,
they were placed in the test room 1 h before the test. The paw test
was performed 30 min after drug or vehicle administration (1 h for
haloperidol and its vehicle). The rat was held behind the forelimbs. Its
hindlimbs were gently placed in the respective holes, and then the
forelimbs were introduced to the other holes. The latencies for the rat
to withdraw its forelimbs (forelimb retraction time [FRT]) and
hindlimbs (hindlimb retraction time [HRT]) were recorded in three
trials each, conducted 10 min apart. The minimum retraction time
was 1 s, even when the rat immediately withdrew its paw or did not
permit its forelimbs to be placed in the hole. The average FRT and HRT
(mean of three trials) of each rat were then calculated and analyzed
(Ellenbroek et al., 2001).
2.3.4. Locomotor activity
Spontaneous locomotor activity was measured in activity chambers
(40×20×26 cm) equipped with three photocells on the walls (10 cm
apart). The lateral walls were made of wood, the ﬂoor was made of
wired mesh, and the top was made of dark green Plexiglas. The level
of illumination on the ﬂoor of the apparatus was 20 lx. The mice
were individually placed in the activity chambers, and the numbers of
beam interruptions were cumulatively recorded for a period of 20 min
(Camarini et al., 1995).
2.4. Statistical analysis
The total apomorphine-induced stereotypy scores, climbing
scores, catalepsy (with vehicle pretreatment), and locomotor activity
data were analyzed by one-way analysis of variance (ANOVA),
with treatment as a factor, followed by the Newman–Keuls test.
Catalepsy (haloperidol pretreatment and treatment factors) scores
was analyzed by two-way ANOVA followed by the Newman–Keuls
test. The latencies to withdraw the limbs in the paw test were
analyzed by a nonparametric Kruskal–Wallis ANOVA followed by the
multiple comparison test. All statistical analyses were performed
using Statistica 7.0 software (Statsoft) or Prism 5.0 software (Graph-
Pad). Statistically signiﬁcant differences were set at pb0.05.
3. Results
3.1. Stereotypy
Olanzapine (10 mg/kg) blocked apomorphine-induced stereotypy
(Fig. 2). The total stereotypy score was reduced by olanzapine
(F7,59=122.71, pb0.001; Fig. 2). Apomorphine-induced stereotypy
was also blocked by 10 mg/kg myricitrin (Fig. 2). The total stereotypy
score was dose-dependently blocked by myricitrin, and a lower dose
(5 mg/kg) did not induce any signiﬁcant effects. At the doses tested,
myricitrin alone did not induce stereotypy.
7-Nitroindazole had a dose-response effect on total apomorphine-
induced stereotypy scores. A high 7-NI dose (6 mg/kg) blockedstereotypy, and the effects of a low dose were not different from
the vehicle+apomorphine group (F5,33=62.09, pb0.001; Fig. 3).
Tamoxifen (1.0 mg/kg) also blocked apomorphine-induced stereotypy
(F3,32=118.00, pb0.001; Fig. 4).
Pretreatment with L-arginine (200–600 mg/kg) reversed the effect
of 7-NI (F15,80=26.38, pb0.001; Fig. 5) on apomorphine-induced
stereotypy (total score), but the reversal of the effect of myricitrin
(10 mg/kg)was only partial (F7,44=110.44, pb0.001; Fig. 6). Although
myricitrin signiﬁcantly reduced the total stereotypy score compared
with the apomorphine+saline group, the effect still differed signif-
icantly from the saline+saline group.
A signiﬁcant effect of co-administration of subeffective doses of
myricitrin (5.0 mg/kg) and olanzapine (1.0 mg/kg) was observed on
apomorphine-induced stereotypy (F7, 40=165.100, pb0.0001; Fig. 7).
Myricitrin+olanzapine co-administration reduced stereotypy com-
pared with the other groups treated with apomorphine (all pb0.001).
However, all of theapomorphine-treatedgroups (includingmyricitrin+
olanzapine) were different from the control group (saline+saline+
saline; all pb0.05). Thus, the myricitrin+olanzapine combination only
partially blocked apomorphine-induced stereotypy.3.2. Climbing
Myricitrin (5 and 10 mg/kg) and olanzapine inhibited the total
score of apomorphine-induced climbing (F7,58=6.89, pb0.001;
Fig. 2). 7-Nitroindazole at the high dose (6 mg/kg; F5,33=2.62,
pb0.02) and tamoxifen (F3,32=3.64, pb0.02) reduced the total
score of apomorphine-induced climbing (Figs. 3 and 4, respectively).
Pretreatment with L-arginine (200–600 mg/kg) reversed the effects
of 7-NI (F15,95=3.63, pb0.001; Fig. 5), but only partially inhibited
the effect of myricitrin (F7,44=2.65, pb0.02; Fig. 6).
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apomorphine-induced climbing (F7,40=7.084, pb0.001; Fig. 7). How-
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(pb0.05) compared with saline+saline+apomorphine.
3.3. Paw test
As shown in Fig. 8A, haloperidol impaired FRT and HRT at 1 mg/kg
compared with saline (FRT: H2,18=7.12, pb0.05; HRT: H2,18=12.49,A
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Fig. 8. Effects of (A) 0.5 and 1.0 mg/kg haloperidol, (B) 1, 5, and 10 mg/kg olanzapine, (C) 10
forelimb retraction time (FRT) and hindlimb retraction time (HRT) in the paw test. Data
compared with saline; #pb0.05, compared with olanzapine (1 and 5 mg/kg).pb0.01). As shown in Fig. 8, olanzapine impaired HRT at 5 and
10 mg/kg (H3,20=15.80, pb0.001), doses that did not modify FRT
(H2,18=3.00, pN0.05). As shown in Fig. 8C, myricitrin 10 and
30 mg/kg impaired HRT only (FRT: H2,29=0.00, pN0.05; HRT:
H2,29=16.01, pb0.001). Tamoxifen did not have any effect in the
paw test (Fig. 8D), and 7-NI at a dose of 6 mg/kg impaired HRT only
(HRT: H2,21=14.09, pb0.001; FRT: H2,21=0.00, pN0.05; Fig. 8D).
3.4. Catalepsy test
The ANOVA showed a signiﬁcant effect of haloperidol pretreatment
(F2,96=108.43, pb0.001) but no effect of treatment (F3,96=2.57,
p=0.059) and no treatment interaction (F6,96=1.04, pN0.05). Halo-
peridol dose-dependently increased catalepsy time (all pb0.001).
Myricitrin and olanzapine alone did not increase the latency for the
mice to withdraw their forepaws from the bar (F3,32=1.00, pN0.05;
Fig. 9).
3.5. Locomotor activity
At the doses tested, myricitrin did not alter spontaneous locomotor
activity (F2,24=1.17, pN0.20; mean±SEM: saline, 88±9; myricitrin
10 mg/kg, 75±6; myricitrin 30 mg/kg, 72±7; n=8–10/group).
4. Discussion
Myricitrin is hypothesized to exert a positive effect in animal
models used in the search for putative antipsychotic-like drugs. The
predictive validity of these animal models is based on a comparison
of the test drug with a well-established antipsychotic drug such as
haloperidol or olanzapine. Considering that both conventional and
atypical antipsychotics blocked apomorphine-induced climbing and
stereotypy (Bardin et al., 2006; Costall et al., 1978; Depoortere et al.,
2003) and affect HRT in the paw test (Ellenbroek et al., 1987), the
activity of myricitrin in these models suggests that it could be a
putative antipsychotic-like drug for the positive symptoms of
schizophrenia. Importantly, these effects were seen at doses that did
not affect spontaneous locomotor activity or induce catalepsy. This*
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Fig. 9. Effects of olanzapine, myricitrin, or saline in the catalepsy (bar) test, with and
without haloperidol pretreatment (0.25 and 1.0 mg/kg, i.p.). Sal, saline; Myr10, 10 mg/kg
myricitrin; Myr30, 30 mg/kg myricitrin; Olanz: 10 mg/kg olanzapine. Data are expressed
as mean+SEM (n=9–10 per group). ***pb0.001, compared with saline; ###pb0.001,
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observed in the present study, which was similar to olanzapine.
7-Nitroindazole, a speciﬁc neuronal NO inhibitor, also reduced
apomorphine-induced stereotypy and climbing, which is consistent
with previous studies of methylphenidate-induced disruptions of
prepulse inhibition (Issy et al., 2009). The effect of 7-NI was reversed
by L-arginine, suggesting mediation by NO inhibition. L-arginine only
partially reversed the myricitrin-induced blockade of apomorphine-
induced stereotypy, which also suggests NO mediation (Fig. 1). The
effect of L-arginine on apomorphine-induced climbing was less clear;
although a similar pattern was observed, no signiﬁcant effect was
seen. This result is complicated by L-arginine's effect on climbing,
which may have been attributable to an increase in NO, which
increases synaptic dopamine by facilitating its release and blocking its
reuptake (Del Bel et al., 2005; West et al., 2002). However, L-arginine
would be expected to potentiate the effect of apomorphine, but
no difference was found between the saline+apomorphine group
and L-arginine+apomorphine group. Altogether, the present results
suggest that both nitrergic and non-nitrergic actions contribute to
the antipsychotic-like effects of myricitrin. Supporting the proposed
involvement of nitrergic and non-nitrergic mechanisms in myricitrin-
induced inhibition of apomorphine-induced stereotypy, tamoxifen,
a PKC inhibitor, also inhibited this behavior, indicating the PKC
inhibition also exerts an antipsychotic-like effect in these models.
Although an antidopaminergic effect of drugs that inhibit NO
transmission, such as myricitrin and 7-NI, is predictable based on
previous studies (Bernstein et al., 2005; Del Bel et al., 1998, 2002, 2005;
Issy et al., 2009; Salumet al., 2006;West et al., 2002;Wiley, 1998), these
studies demonstrated an indirect effectmediatedby changes in synaptic
dopamine levels via facilitation of its release or uptake inhibition.
The present results with apomorphine indicate an additional effect on
D2 receptor activation or an intracellular postsynaptic mechanism.
Administration of S-nitroso-N-acetylpenicillamine (SNAP), a NO donor,
reversed the inhibitory effect of 3-(R)-2-carboxypiperazin-4-propyl-1-
phosphonic acid (CPP) on apomorphine-induced climbing, whereas
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), a NO
inhibitor, decreased the facilitatory effect of N-methyl-D-aspartate
(NMDA) on apomorphine-induced climbing (Hong et al., 2005). This
direct positive effect of NO on dopamine receptors was previously
suggested by Hong et al. (2005). Thus, in addition to a decrease in the
NO inhibitory effect on dopamine uptake, additional mechanisms
related to postsynaptic D2 receptor activation may be involved in
the antipsychotic-like effect of myricitrin and other NO inhibitors
(e.g., 7-NI; Fig. 1). However, the present results contrast with
Salum et al. (2006), whom did not ﬁnd any effect of NO inhibitorson prepulse inhibition disruption induced by dopamine agonists,
including apomorphine.
The paw test is an animal model of antipsychotic-like action and
extrapyramidal side effects that has good pharmacological predictive
validity (Ellenbroek and Cools, 1988; Geyer and Ellenbroek, 2003).
The results with haloperidol and olanzapine conﬁrm previous
ﬁndings, in which typical antipsychotics enhanced FRT and HRT at
the same dose, whereas atypical antipsychotics increased FRT at a
higher dose than the one that increased HRT (Cools et al., 1995;
Ellenbroek et al., 1996, 2001; Ellenbroek and Cools, 1988). Myricitrin
had an atypical antipsychotic proﬁle because it increased HRT at a
lower dose than the one that increased FRT. This result is supported
by the lack of an effect of myricitrin in the catalepsy test at a dose
that blocked the effects of apomorphine. Tamoxifen did not change
retraction times in the paw test, suggesting that PKC inhibition cannot
fully explain the antipsychotic-like effects of myricitrin.
Although 7-NI had a signiﬁcant effect on HRT, this effect appeared
to be smaller (nearly 2 s) than olanzapine and other antipsychotics
(10–20 s). However, this effect may indicate NO activity, which is
consistent with other animal models (Del Bel et al., 1998, 2005) and
the present apomorphine-induced stereotypy and climbing results.
Themyricitrin+olanzapine combination showed promising results.
Subeffective doses of these drugs were able to block the stereotypy
induced by apomorphine when co-administered. Conversely, no
conclusion can bedrawn from the analysis of climbingbehavior because
the myricitrin dose used for this experiment already blocked climbing
induced by apomorphine. This result was also observed in the
ﬁrst experiment in the present study. Altogether, these results indicate
that myricitrin exhibits an effect proﬁle that is similar to atypical
antipsychotic drugs. For apomorphine-induced behaviors, a higher dose
is necessary to block stereotypy than to block climbing (Geyer and
Ellenbroek, 2003), which is consistent with the effects of myricitrin in
the paw test and on catalepsy.
The dose of myricitrin used in the present study did not induce
catalepsy or alter spontaneous locomotor activity, which is consistent
with previous studies that used a similar dose range (Fernandez et al.,
2009; Meotti et al., 2006a). No speciﬁc or systematic study has
investigated the potential side effects of myricitrin. However, the
studies cited earlier did not ﬁnd any overt signs of toxicity after acute
administration. Meotti et al. (2006a) did not observe a decrease in
locomotor activity, changes in body temperature, or any other adverse
side effects of myricitrin administration (30–100 mg/kg). No sedative
effects were seen in the elevated plus maze, locomotor activity test,
and horizontal wire test (Fernandez et al., 2009).
Theoverall behavioral proﬁle ofmyricitrinwas similar to theatypical
antipsychotic olanzapine in models that evaluated positive symptoms
(i.e., apomorphine-induced stereotypy and climbing and the paw
test) and catalepsy (i.e., catalepsy test and paw test). Considering the
behavioral tests employed here, atypical antipsychotics are proposed to
have less of an effect on apomorphine-induced stereotypy, FRT in the
paw test, and catalepsy than typical antipsychotics (Bardin et al., 2006;
Geyer and Ellenbroek, 2003). Both typical and atypical antipsychotics
are effective in apomorphine-induced climbing and HRT in the paw
test. The present results partially support this proposal. Olanzapine also
blocked apomorphine-induced stereotypy. Interestingly, these results
are consistent with the idea that striatal D2 blockade is correlated with
improvements in positive symptoms in schizophrenia patients (Agid
et al., 2007), and stereotypy induced by dopamine agonists is related
to D2 receptor activation in the striatum (Porsolt et al., 1993, 2010).
Moreover, climbing behaviorwas suppressed by striatal lesions (Protais
et al., 1976), and a correlation was found between D2 striatal receptor
blockade and apomorphine-induced climbing (Assié et al., 2006).
However, although the present results suggest an atypical proﬁle for
myricitrin, the models used here did not evaluate the negative
symptoms of schizophrenia (Porsolt et al., 2010), which is an important
aspect of atypical antipsychotics.
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In conclusion, myricitrin showed antipsychotic-like effects in
animal models (i.e., apomorphine-induced climbing and stereotypy
and the paw test) at doses that did not induce catalepsy or alter
locomotor activity, suggesting that myricitrin may be a potential drug
treatment for the positive symptoms of schizophrenia.
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